25
Participants
Start Date
November 8, 2021
Primary Completion Date
April 2, 2024
Study Completion Date
April 2, 2024
RXC004
"RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy)~Dose Formulation: 0.5 mg or 1 mg capsules."
Nivolumab
Nivolumab will be administered via IV infusion, 480 mg q4w.
Denosumab
"Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month.~Use: Prophylactic"
Severance Hospital, Yonsei University Health System - Medical Oncology, Seoul
Asan Medical Center - Oncology, Seoul
Samsung Medical Center - Hematology-Oncology, Seoul
National Cancer Center, Goyang-si
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Virgen del Rocio, Seville
Community Health Network Cancer Center North - Community Hospital Network, Indianapolis
Lumi Research, Kingswood
OptumCare Cancer Care, Las Vegas
Providence Medical Foundation, Santa Rosa
UT MD Anderson Cancer Center, Houston
Seoul National University Hospital, Seoul
Hospital del Mar, Barcelona
Hospital Universitario Vall d'Hebrón, Barcelona
Hospital Clìnic de Barcelona, Barcelona
Beatson West of Scotland Cancer Centre - Oncology, Glasgow
Queen Elizabeth Hospital - Clinical Reasearch, Birmingham
University College of London (UCL), London
The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital, London
Christie Hospital, Manchester
Oxford Cancer Centre, Oxford
The Royal Marsden Hospital (Surrey), Surrey Quays
Redx Pharma Ltd
INDUSTRY